Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

被引:30
|
作者
Yang, Yue [1 ]
Keene, C. Dirk [1 ]
Peskind, Elaine R. [2 ,3 ]
Galasko, Douglas R. [4 ]
Hu, Shu-Ching [5 ]
Cudaback, Eiron [1 ]
Wilson, Angela M. [1 ]
Li, Ge [2 ]
Yu, Chang-En [6 ,7 ]
Montine, Kathleen S. [1 ]
Zhang, Jing [1 ]
Baird, Geoffrey S. [1 ,8 ]
Hyman, Bradley T. [9 ]
Montine, Thomas J. [1 ]
机构
[1] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[3] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA USA
[4] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[5] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
[6] Univ Washington, Dept Med, Seattle, WA 98195 USA
[7] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA
[8] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[9] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA
关键词
Alzheimer disease; Biomarkers; Cerebrospinal fluid; Cognitive impairment; Neurodegenerative disease; Parkinson disease; APOLIPOPROTEIN-A-I; AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM; E APOE POLYMORPHISM; TARGETED REPLACEMENT; MEMBRANE-VESICLES; MOUSE MODEL; CIRCULATING MICROPARTICLES;
D O I
10.1097/NEN.0000000000000207
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ-, and amyloid (A) (42)-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE epsilon 4/epsilon 4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level versus those in APOE epsilon 3/epsilon 3 or APOE epsilon 3/epsilon 4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. Cerebrospinal fluid apoE-positive and -amyloid (A(42))-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients versus age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.
引用
收藏
页码:672 / 687
页数:16
相关论文
共 50 条
  • [41] From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease
    Zetterberg, Henrik
    Blennow, Kaj
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 : S271 - S279
  • [42] Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease
    Isobe, C
    Murata, T
    Sato, C
    Terayama, Y
    LIFE SCIENCES, 2005, 77 (15) : 1836 - 1843
  • [43] Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease
    Weinshel, Sarah
    Irwin, David J.
    Zhang, Panpan
    Weintraub, Daniel
    Shaw, Leslie M.
    Siderowf, Andrew
    Xie, Sharon X.
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (04) : 1155 - 1167
  • [44] Decreased Cerebrospinal Fluid Aβ42 in Patients with Idiopathic Parkinson's Disease and White Matter Lesions
    Markaki, Ioanna
    Klironomos, Stefanos
    Svenningsson, Per
    JOURNAL OF PARKINSONS DISEASE, 2019, 9 (02) : 361 - 367
  • [45] A comparison of early diagnostic utility of Alzheimer disease biomarkers in brain magnetic resonance and cerebrospinal fluid
    Monge Argiles, J. A.
    Blanco Canto, M. A.
    Leiva Salinas, C.
    Flors, L.
    Munoz Ruiz, C.
    Sanchez Paya, J.
    Gasparini Berenguer, R.
    Leiva Santana, C.
    NEUROLOGIA, 2014, 29 (07): : 397 - 401
  • [46] Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease
    Alawode, D. O. T.
    Heslegrave, A. J.
    Ashton, N. J.
    Karikari, T. K.
    Simren, J.
    Montoliu-Gaya, L.
    Pannee, J.
    O'Connor, A.
    Weston, P. S. J.
    Lantero-Rodriguez, J.
    Keshavan, A.
    Snellman, A.
    Gobom, J.
    Paterson, R. W.
    Schott, J. M.
    Blennow, K.
    Fox, N. C.
    Zetterberg, H.
    JOURNAL OF INTERNAL MEDICINE, 2021, 290 (03) : 583 - 601
  • [47] Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease
    Backstrom, David C.
    Domellof, Magdalena Eriksson
    Linder, Jan
    Olsson, Bob
    Ohrfelt, Annika
    Trupp, Miles
    Zetterberg, Henrik
    Blennow, Kaj
    Forsgren, Lars
    JAMA NEUROLOGY, 2015, 72 (10) : 1175 - 1182
  • [48] Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients
    Hu, YY
    He, SS
    Wang, XC
    Duan, QH
    Khatoon, S
    Iqbal, K
    Grundke-Iqbal, I
    Wang, JZ
    NEUROSCIENCE LETTERS, 2002, 320 (03) : 156 - 160
  • [49] Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease
    Wang, Lijun
    Gao, Tianhao
    Cai, Tengteng
    Li, Kunyi
    Zheng, Ping
    Liu, Jun
    NEUROSCIENCE LETTERS, 2020, 715
  • [50] Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer's Disease
    Aksnes, Mari
    Tiiman, Ann
    Edwin, Trine Holt
    Terenius, Lars
    Bogdanovic, Nenad
    Vukojevic, Vladana
    Knapskog, Anne-Brita
    FRONTIERS IN AGING NEUROSCIENCE, 2021, 12